secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001517022-24-000075
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q3 2024 net loss $20M; Vafseo launch on track for Jan 2025 with 60% dialysis patient coverage
--------------------------------------------------------------------------------

- Total revenues $37.4M in Q3 2024 vs $42.0M in Q3 2023, driven by Auryxia volume decline.
- Net loss $20.0M in Q3 2024 vs $14.5M in Q3 2023, including $4.4M non-cash interest from Vifor settlement.
- Cash and equivalents $34.0M as of Sep 30, 2024; company expects funding to cover operations including Vafseo launch for at least two years.
- Vafseo commercial supply contracts cover over 300,000 patients (~60% of US dialysis patients); TDAPA reimbursement starts Jan 1, 2025.
- U.S. market availability for Vafseo expected in January 2025; VOICE trial initiated with US Renal Care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000075/0001517022-24-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000075/akba-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer